Lexicon Pharmaceuticals, Inc.
HealthcareNASDAQ:LXRX · NASDAQ Global Select
+$0.03 today
Vol 2.99M · Avg 2.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-46.8%
avg -72.4%
ROIC
-28.7%
avg -40.5%
ROA
-27.2%
avg -35.3%
Analysis
ROA is currently the strongest return metric at -27.2% versus its period average of -35.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Exton | Chief Executive Officer & Director | $1.15M | — | 56 | $1.01M | 0.23% |
Craig Granowitz | Senior Vice President & Chief Medical Officer | $789,535.00 | — | 61 | $432,528.00 | 0.10% |
Brian T. Crum | Senior Vice President, General Counsel & Secretary | $687,366.00 | — | 53 | $428,802.00 | 0.10% |
Scott Coiante | Senior Vice President & Chief Financial Officer | $646,287.00 | — | 59 | $320,473.00 | 0.07% |
Wendy E. McDermott | Senior Vice President of Human Resources | $580,446.00 | — | 55 | $126,122.00 | 0.03% |
Kristen L. Alexander | Vice President of Finance & Accounting | $379,807.00 | — | 58 | $94,230.00 | 0.02% |
Suma Gopinathan | Senior Vice President of Discovery | — | — | 53 | $174,470.00 | 0.04% |
Lisa DeFrancesco | Senior Vice President of Investor Relations & Corporate Communications | — | — | 46 | $256,380.00 | 0.06% |
Rachel Yap Martens | Senior VP of Partnerships & Corporate Strategy | — | — | 42 | $134,180.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$2.72M
Sells
0
$0.00
Net Sentiment
+$2.72M
Net buying
Most Active
DEBBANE RAYMOND
7 transactions
Analysis
Insiders reported 8 buys worth $2.72M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.72M. DEBBANE RAYMOND was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +392.4% | -1.2% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +392.4% over three years. Forward estimates point to Revenue at -1.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Omeros Corporation
NASDAQ:OMER
$632.20M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages LXRX?
Lexicon Pharmaceuticals, Inc. (LXRX) lists 9 active executives. The top listed executive is Brian T. Crum, Senior Vice President, General Counsel & Secretary.
Are LXRX insiders buying or selling?
Recent insider activity shows net buying of $69.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.